A composition, comprising a hydrogel matrix and microparticles within said matrix, said matrix comprising a cross-linkable protein and a cross-linking agent, wherein said cross-linking agent is able to cross-link said cross-linkable protein, wherein said microparticles comprise a drug.

The present invention provides a medical dressing article and a method of manufacturing the same, which comprises: (a) a first layer comprised of polycaprocaptone fibers having a PCL fiber diameter of 0.5 μm and 2.9 μm; (b) a second layer, deposited directly on the first layer, including a mixture of polycaprolactone and poloxamer fibers (PCL and POX fibers) wherein a PCL and POX fiber diameter is between 0.1 μm and 4 μm; and (c) a third layer, deposited directly on the second layer, further comprising a mixture of gelatin and silver nitrate (AgNO.sub.3).

The present invention is generally directed to cannabinoid medical carriers that are effective in the treatment of internal wounds, such as brain or spinal cord injury. One embodiment comprises a application device consisting of a dissolvable biological carrier that contains a cannabinoid, which is readily adsorbed in vivo and is capable of conforming to the size and shape of the surface of the contusion site of a neurological trauma. The various elements of the medical carrier can be saturated with cannabidiol or other phytocannabinoids by diffusion under sterile conditions to achieve medicinal concentrations. The carrier can be applied through open or semi-open surgical procedures, or epidural or by subarachnoid/intrathecal delivery.

A dispensing system includes a hollow tube having an outer wall with an air vent formed in the outer wall. A valve including a flexible flap is disposed inside the tube. The flexible flap, normally biased into a retracted position, is moveable between an extended position for sealing the air vent and the retracted position for unsealing the air vent. A syringe connector interconnects a syringe with the proximal end of the hollow tube and defines a fluid flow path. A flowable viscous fluid is disposed within the syringe. When a syringe plunger is depressed, the flowable viscous fluid is expelled from the syringe and forced through the fluid flow path and into the proximal end of the hollow tube. When the flowable viscous fluid engages the flexible flap, the flexible flap is forced to move into a position that seals the air vent.

Polymeric compositions, methods, and delivery devices for inhibiting bleeding are disclosed. The method includes applying a dried material topically to a wound site, where the material may include a cross-linked biologically compatible polymer which forms a hydrogel when exposed to blood and where the material may not include an active agent such as thrombin. A spring-loaded delivery device as described herein may be used to apply the dried material.

Thus, the present invention provides a composition in powder form comprising highly dispersed silica particles, polymethylsiloxane particles, and a cationic surfactant, wherein at least 25% by weight of the cationic surfactant is present in primary polymethylsiloxane particles carrying the cationic surfactant on their surface and/or in agglomerates of these primary particles.

To provide a liquid medical material maintaining a colloid in a more sol form than a solid at normal temperature, having a higher function as a wound dressing material and a hemostatic material than fibrin glue, and being able to be produced safely and inexpensively. A gelatin aqueous solution including calcium at a concentration of 0.2 M or more and 1.0 M or less, and having a concentration of 5% by weight or more and 40% by weight or less, an average molecular weight of 80,000 or more and 120,000 or less, and a molecular weight distribution of 20,000 or more and 300,000 or less, and transglutaminase inducing crosslinking of the gelatin, are included. It is preferable that the calcium has a concentration of 0.2 M or more and 0.7 M or less, the gelatin has a bloom of 160 or more and 250 or less, and the transglutaminase has activity per unit of 36 U/ml to 400 U/ml.

Disclosed is a thrombin-free, liquid biological glue for therapeutic use, including fibrinogen and factor VIIa. The ratio of fibrinogen concentration to FVIIa concentration is 20000:1 to 1000:1, with the concentrations being expressed in weight per volume. The fibrinogen concentration is lower than 60 mg/ml. Also disclosed are a kit for preparing such a biological glue, a method to prepare the glue, and a medicament.

An isotonic irrigation solution for wounds, surgical incisions and as a lavage, the irrigation solution comprising saline, antimicrobial, chelator, surfactant and collagenous biological enhancer.

The present disclosure relates to a method for vacuum expansion of a paste prior to freeze-drying said paste to achieve a dry paste composition which reconstitutes efficiently to form a flowable paste upon addition of an aqueous medium. The present disclosure further relates to a syringe for retaining a dry paste composition in a vacuum.